UBMD Pediatrics
Welcome,         Profile    Billing    Logout  
 18 Trials 
44 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Haller, Michael J
INHALE-1, NCT04974528: Afrezza® Study in Pediatrics

Active, not recruiting
3
319
US
Afrezza, Technosphere Insulin, Rapid-acting Insulin Analog, insulin aspart, insulin lispro, insulin glulisine, Novolog®, Fiasp®, Humalog®, Admelog®, Apidra®, Basal Insulin, insulin glargine, insulin degludec, insulin detemir, Lantus®, Abasaglar®, Basaglar®, Semglee®, Toujeo®, Tresiba®, Levemir®
Mannkind Corporation, Jaeb Center for Health Research
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
10/24
05/25
NCT03961854: Lactobacillus Johnsonii in Children and Adolescents With T1D

Recruiting
2
57
US
L. johnsonii Probiotic, Placebo Capsule
University of Florida, Juvenile Diabetes Research Foundation
Type 1 Diabetes (T1D)
03/26
03/26
NCT03961347: Lactobacillus Johnsonii Supplementation in Adults With T1D

Recruiting
2
57
US
L. johnsonii Probiotic, Placebo Capsule
University of Florida, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 1 Diabetes (T1D)
06/26
06/26
NCT05743244: Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

Recruiting
2
78
US
Abrocitinib 200 MG Oral Tablet, CIBINQO, Ritlecitinib, Placebo
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Pfizer
Diabetes Mellitus, Type 1
06/26
06/27
NCT03929601: Rituximab-pvvr and Abatacept Vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

Recruiting
2
74
US, RoW
Rituximab-pvvr, Ruxience, Abatacept, Orencia, Sterile Sodium Chloride, 0.9% Sodium Chloride Water for Injection
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH)
Type 1 Diabetes Mellitus
10/27
10/29
TN28, NCT04291703: STOP-T1D Low-Dose (ATG)

Active, not recruiting
2
101
US, RoW
Antithymocyte Globulin, Thymoglobulin, Placebo (for ATG)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 1
12/28
12/29
TOPPLE T1D, NCT04279613: A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041

Completed
1
47
US
NNC0361-0041, Placebo
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Novo Nordisk A/S
Type I Diabetes
08/23
04/24
ECHO, NCT06552923: Extension for Community Health Outcomes () Diabetes Program

Completed
N/A
32796
US
ECHO Tele-Education
University of Florida
Type 1 Diabetes, Type 2 Diabetes
06/22
12/23
NCT02234947: Pancreas Volume in Preclinical Type 1 Diabetes

Completed
N/A
246
US
MRI, US, and blood samples, Magnetic Resonance Imaging, Ultrasounography
University of Florida, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Diabetes Action Research and Education Foundation
Type 1 Diabetes
04/23
04/23
NCT06348160: iHERO Study: Insurance, Health and Economic Resources Online for Emerging Adults With Type 1 Diabetes

Recruiting
N/A
192
US
iHERO Toolkit Resource
Julia Blanchette, The Leona M. and Harry B. Helmsley Charitable Trust
Type 1 Diabetes
03/26
03/26
NCT06719531: SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients with Type 1 and Type 2 Diabetes

Not yet recruiting
N/A
1500
US
Continuous Glucose Monitoring
Medtronic Diabetes
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
12/25
12/25
NCT00097292: TrialNet Pathway to Prevention of T1D

Recruiting
N/A
75000
Europe, Canada, US, RoW
University of South Florida, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), American Diabetes Association, National Institute of Allergy and Infectious Diseases (NIAID), National Center for Research Resources (NCRR)
Diabetes Mellitus, Type 1
07/25
07/25
Jones, Rachel
NANO, NCT03997266: NICU Antibiotics and Outcomes Trial

Recruiting
4
802
Canada, US
Ampicillin, Gentamycin, Normal saline
Michael Morowitz, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Microbial Colonization, Extreme Prematurity, Early-Onset Neonatal Sepsis, Late-Onset Neonatal Sepsis, Necrotizing Enterocolitis of Newborn, Death; Neonatal
09/26
06/27
ICON9, NCT03278717 / 2017-000161-75: Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients

Recruiting
3
330
Europe, Canada, RoW
Olaparib, Cediranib
University College, London, Cancer Research UK, AstraZeneca UK Limited
Ovarian Cancer
12/23
12/23
GOOD-IDES-02, NCT05679401: A Study With Imlifidase in Anti-GBM Disease

Active, not recruiting
3
50
Europe, US, RoW
Imlifidase, IdeS, HMED-IdeS, Plasma exchange (PLEX), PE, Cyclophosphamide (CYC), Glucocorticoids
Hansa Biopharma AB
Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
06/25
11/26
NCT05678959: Long-term Extension Study of Ligelizumab in Food Allergy

Active, not recruiting
3
165
Europe, Canada, Japan, US, RoW
Ligelizumab 120 mg, Ligelizumab 240 mg
Novartis Pharmaceuticals
Food Allergy
02/25
02/25
COMBIVAS, NCT03967925 / 2017-004645-24: Rituximab and Belimumab Combination Therapy in PR3 Vasculitis

Active, not recruiting
2
31
Europe
Belimumab, Benlysta, Rituximab, Truxima, Prednisolone, prednisone
Rachel Jones, GlaxoSmithKline, Medical Research Council, Imperial College London, University College, London, Newcastle University, University of Glasgow, University of Cambridge
ANCA Associated Vasculitis, Granulomatosis With Polyangiitis
04/23
11/23
RACEMATE, NCT06230354: Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis

Enrolling by invitation
2
66
Europe
Tezepelumab, Placebo
Imperial College London, AstraZeneca
EGPA - Eosinophilic Granulomatosis With Polyangiitis
10/25
10/25
NCT04189939: Computational Psychiatric Approach to Depression

Completed
N/A
128
US
clinical assessments, computer-based decition making task, 3T MRI scan
Wake Forest University Health Sciences
Depression, Treatment Resistant Depression
05/23
07/23
NCT05214989: Tailored Interventions to Increase Cardiac Rehabilitation Enrollment

Withdrawn
N/A
25
US
Tailored intervention
VA Office of Research and Development
Cardiovascular Disease
01/25
01/25
Huang, Taosheng
NCT04594590: Natural History Study of SLC25A46 Mutation-related Mitochondriopathy

Completed
N/A
9
US
Mutation analysis
State University of New York at Buffalo, Hadley Jo Foundation
Neurodegenerative Disease, Hereditary, Mitochondrial Diseases, Optic Atrophy
08/23
08/23
NCT04580979: Natural History Study of FDXR Mutation-related Mitochondriopathy

Completed
N/A
33
US
Mutation analysis
State University of New York at Buffalo, The Callum McKeefery and Nikki Albano McKeefery Pediatric Division of Genetics Fund
Neurodegenerative Disease, Hereditary, Mitochondrial Diseases, Optic Atrophy
08/23
08/23
Quattrin, Teresa
OraGrowtH210, NCT04614337 / 2020-000874-92: Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency ( Trial)

Completed
2
82
Europe, US, RoW
LUM-201, rhGH Norditropin® pen (34 µg/kg)
Lumos Pharma, Lumos Pharma
Growth Hormone Deficiency
09/24
09/24
NCT05743244: Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

Recruiting
2
78
US
Abrocitinib 200 MG Oral Tablet, CIBINQO, Ritlecitinib, Placebo
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Pfizer
Diabetes Mellitus, Type 1
06/26
06/27
FBT for T1D, NCT05756361: Family-Based Treatment for Type 1 Diabetes

Recruiting
N/A
20
US
Family-Based Treatment for T1D
State University of New York at Buffalo, National Center for Advancing Translational Sciences (NCATS)
Diabetes Mellitus, Type 1, Obesity, Childhood, Overweight, Comorbidities and Coexisting Conditions
10/24
12/24
Bethin, Kathleen
INHALE-1, NCT04974528: Afrezza® Study in Pediatrics

Active, not recruiting
3
319
US
Afrezza, Technosphere Insulin, Rapid-acting Insulin Analog, insulin aspart, insulin lispro, insulin glulisine, Novolog®, Fiasp®, Humalog®, Admelog®, Apidra®, Basal Insulin, insulin glargine, insulin degludec, insulin detemir, Lantus®, Abasaglar®, Basaglar®, Semglee®, Toujeo®, Tresiba®, Levemir®
Mannkind Corporation, Jaeb Center for Health Research
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
10/24
05/25
RescuiNGkids, NCT04992312 / 2021-006088-61: A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes

Completed
1
7
US
Glucagon Nasal Powder [Baqsimi], LY900018, Baqsimi
Eli Lilly and Company, Eli Lilly and Company
Type 1 Diabetes
11/23
11/23
NCT06362265: A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus

Recruiting
1
22
US
LY3209590
Eli Lilly and Company
Type 2 Diabetes Mellitus
11/26
11/26
Mastrandrea, Lucy
NCT02516657: Liraglutide in Adolescents With Type 1 Diabetes

Active, not recruiting
3
5
US
Liraglutide, Victoza
University at Buffalo
Type 1 Diabetes
12/23
12/24
SURMOUNT-ADOLESCENTS-2, NCT06439277: A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities

Recruiting
3
300
Europe, Canada, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Weight Gain
05/27
06/27
NCT04628481 / 2020-001926-71: A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function

Active, not recruiting
2
140
Europe, US, RoW
Ladarixin, allosteric inhibitor of CXCL8 (IL-8), CXCR1 and CXCR2 receptors, Placebo
Dompé Farmaceutici S.p.A, Dompe farmaceutici s.p.a.
Recent Onset type1 Diabetes
04/24
04/26
NCT05540132: Slow Digestible Carbohydrates and Exercise in Adolescents with Type 1 Diabetes

Active, not recruiting
N/A
20
US
maltodextrin, super starch
State University of New York at Buffalo
Type 1 Diabetes, Hypoglycemia
10/25
06/26
House, Amanda J
INHALE-1, NCT04974528: Afrezza® Study in Pediatrics

Active, not recruiting
3
319
US
Afrezza, Technosphere Insulin, Rapid-acting Insulin Analog, insulin aspart, insulin lispro, insulin glulisine, Novolog®, Fiasp®, Humalog®, Admelog®, Apidra®, Basal Insulin, insulin glargine, insulin degludec, insulin detemir, Lantus®, Abasaglar®, Basaglar®, Semglee®, Toujeo®, Tresiba®, Levemir®
Mannkind Corporation, Jaeb Center for Health Research
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
10/24
05/25
OraGrowtH210, NCT04614337 / 2020-000874-92: Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency ( Trial)

Completed
2
82
Europe, US, RoW
LUM-201, rhGH Norditropin® pen (34 µg/kg)
Lumos Pharma, Lumos Pharma
Growth Hormone Deficiency
09/24
09/24
DESIGNATE, NCT05574335: Siplizumab in T1DM

Active, not recruiting
1/2
120
US
Siplizumab, TCD 601
National Institute of Allergy and Infectious Diseases (NIAID)
Type 1 Diabetes Mellitus
12/26
12/27
Cossen, Kristina
NCT05228184: Use of Tirosint®-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH)

Active, not recruiting
4
126
US
Tirosint®-SOL, levothyroxine sodium oral solution (liquid), Levothyroxine Sodium, levothyroxine sodium tablets
IBSA Institut Biochimique SA, Cromsource
Congenital Hypothyroidism
04/25
04/25
INHALE-1, NCT04974528: Afrezza® Study in Pediatrics

Active, not recruiting
3
319
US
Afrezza, Technosphere Insulin, Rapid-acting Insulin Analog, insulin aspart, insulin lispro, insulin glulisine, Novolog®, Fiasp®, Humalog®, Admelog®, Apidra®, Basal Insulin, insulin glargine, insulin degludec, insulin detemir, Lantus®, Abasaglar®, Basaglar®, Semglee®, Toujeo®, Tresiba®, Levemir®
Mannkind Corporation, Jaeb Center for Health Research
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
10/24
05/25
NCT05378672: A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D

Recruiting
3
8
US
Dasiglucagon, Zegalogue, ZP4207
Zealand Pharma, Novo Nordisk A/S
Hypoglycemia, Type 1 Diabetes
09/24
09/24
NCT06362265: A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus

Recruiting
1
22
US
LY3209590
Eli Lilly and Company
Type 2 Diabetes Mellitus
11/26
11/26
Ikomi, Chijioke
SURMOUNT-ADOLESCENTS-2, NCT06439277: A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities

Recruiting
3
300
Europe, Canada, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Weight Gain
05/27
06/27
SURPASS-PEDS, NCT05260021 / 2021-003612-31: A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

Active, not recruiting
3
99
Europe, US, RoW
Tirzepatide Dose 1, Tirzepatide Dose 2, Placebo
Eli Lilly and Company, Eli Lilly and Company
Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease
07/24
02/25
Lippner, Elizabeth
NCT05678959: Long-term Extension Study of Ligelizumab in Food Allergy

Active, not recruiting
3
165
Europe, Canada, Japan, US, RoW
Ligelizumab 120 mg, Ligelizumab 240 mg
Novartis Pharmaceuticals
Food Allergy
02/25
02/25
adored, NCT05003804: Allergic Disease Onset Prevention Study

Active, not recruiting
1/2
264
US, RoW
STMC-103H, Placebo
Siolta Therapeutics, Inc.
Atopic Dermatitis, Type 1 Hypersensitivity
11/24
10/25
Hassanieh, Ghinwa Al
NCT05678959: Long-term Extension Study of Ligelizumab in Food Allergy

Active, not recruiting
3
165
Europe, Canada, Japan, US, RoW
Ligelizumab 120 mg, Ligelizumab 240 mg
Novartis Pharmaceuticals
Food Allergy
02/25
02/25

Download Options